The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Kremer, J.; Bloom, B.; Breedveld, F.; Coombs, J.; P. Fletcher, M.; Gruben, D.; Krishnaswami, S.; Burgos-Vargas, R.; Wilkinson, B.; Zerbini, C.; Zwillich, S.

doi:10.1002/art.24567

Public

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo

Shared by NobleBlocks on Jun 28, 2009 • 12:00 AM UTC

Authors:

Joel M. Kremer

Bradley J. Bloom

Ferdinand C. Breedveld

Abstract

Abstract Objective To determine the efficacy, safety, and tolerability of 3 different dosages of CP‐690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response. Me...

Discussions